{"nctId":"NCT00954447","briefTitle":"Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes","startDateStruct":{"date":"2009-08"},"conditions":["Diabetes Mellitus, Type 2"],"count":1263,"armGroups":[{"label":"Linagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Linagliptin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Linagliptin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Diabetes type 2, detectable C-peptide, HbA1c 7-10%\n2. Pretreatment with basal insulin +/- Metformin or/and +/- Pioglitazone 3 Age \\> 18 years, BMI \\<= 45 kg/m2\n\nExclusion criteria:\n\n1. Uncontrolled hyperglycemia during Run-in\n2. Myocardial infarction, stroke or TIA within 3 months prior to informed consent\n3. Liver impairment; gastric surgery; medical history of cancer in last 5 years\n4. Other antidiabetic drugs, antiobesity drugs, systemic steroids, other investigational drug before randomisation\n5. Unsufficient birth control, pregnancy and nursing","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c After 24 Weeks","description":"HbA1c is measured as a percentage. Adjusted for treatment, baseline HbA1c, categorical renal function impairment and concomitant Oral antidiabetic drugs (OAD)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.08"},{"groupId":"OG001","value":"-0.58","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With HbA1c < 7.0 Percent","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"134","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"109","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Lowering HbA1c by at Least 0.5 Percent","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":null},{"groupId":"OG001","value":"333","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"231","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c by Visit at Week 6","description":"Means adjusted for treatment, baseline HbA1c, categorical renal function impairment and concomitant OADs","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.05"},{"groupId":"OG001","value":"-0.45","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c by Visit at Week 12","description":"Means adjusted for treatment, baseline HbA1c, categorical renal function impairment and concomitant OADs","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.07"},{"groupId":"OG001","value":"-0.59","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c by Visit at Week 18","description":"Means adjusted for treatment, baseline HbA1c, categorical renal function impairment and concomitant OADs","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.08"},{"groupId":"OG001","value":"-0.64","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c by Visit at Week 32","description":"Means adjusted for treatment, baseline HbA1c, categorical renal function impairment and concomitant OADs","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.08"},{"groupId":"OG001","value":"-0.56","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c by Visit at Week 40","description":"Means adjusted for treatment, baseline HbA1c, categorical renal function impairment and concomitant OADs","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.08"},{"groupId":"OG001","value":"-0.50","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c by Visit at Week 52","description":"Means adjusted for treatment, baseline HbA1c, categorical renal function impairment and concomitant OADs","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.08"},{"groupId":"OG001","value":"-0.48","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at 24 Weeks of Treatment","description":"Means adjusted for treatment, baseline HbA1c, baseline FPG, categorical renal function impairment and concomitant OADs","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.52","spread":"3.94"},{"groupId":"OG001","value":"-7.09","spread":"3.97"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) After 52 Weeks of Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"56.44"},{"groupId":"OG001","value":"-2.55","spread":"55.01"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FPG","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.97","spread":"50.89"},{"groupId":"OG001","value":"-5.29","spread":"44.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":"51.09"},{"groupId":"OG001","value":"-7.59","spread":"48.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.10","spread":"53.21"},{"groupId":"OG001","value":"-3.30","spread":"55.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"54.94"},{"groupId":"OG001","value":"-7.07","spread":"44.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.67","spread":"52.43"},{"groupId":"OG001","value":"-6.30","spread":"48.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.99","spread":"50.29"},{"groupId":"OG001","value":"-6.50","spread":"50.00"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Insulin Dose at 52 Weeks of Treatment","description":"Means adjusted for treatment, continous baseline HbA1c, continous baseline weight, continous baseline Insulin, categorical renal function impairment and concomitant OADs","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.18","spread":"0.84"},{"groupId":"OG001","value":"2.60","spread":"0.84"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Weighted Mean Daily Glucose After 24 and 52 Weeks of Treatment","description":"Mean Daily Glucose was calculated using the 8-point blood glucose profile","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"2.28"},{"groupId":"OG001","value":"-0.01","spread":"1.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"3.06"},{"groupId":"OG001","value":"-0.50","spread":"2.35"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Incremental Post-prandial Glucose (iPPG) After 24 Weeks of Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.31","spread":"44.02"},{"groupId":"OG001","value":"-3.78","spread":"63.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.80","spread":"61.94"},{"groupId":"OG001","value":"-11.00","spread":"68.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.71","spread":"68.15"},{"groupId":"OG001","value":"-3.26","spread":"66.51"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With HbA1c < 6.5 Percent","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":83,"n":630},"commonTop":["Hypoglycaemia","Hyperglycaemia","Nasopharyngitis","Urinary tract infection","Hypertension"]}}}